Semaglutide
Also known as: Semaglutide (GLP-1 agonist)
Semaglutide is a GLP-1 receptor agonist used for type 2 diabetes management and chronic weight management. It mimics the incretin hormone GLP-1 to regulate appetite and glucose metabolism.
Who's worth your money for Semaglutide
Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.
Top Merit pick
Highest Merit Score (99) of 15 scored sellers
$976 · 200mg · 99.9% purity
Best value
Lowest $/mg among scored sellers
$10.00 · 10mg
Most tested
12 independent COAs on file
$130 · 20mg · 99.3% purity
Average price
$7.68/mg
Sellers
27
45-day trend
-1.9%
24 of 27 sellers have a current price· 9 stale hidden
Top Merit pick
🇺🇸 Peptide Partners99via Disclosed Labs · 10h ago
$4.88/mg -36.5% vs avg$976
200mg
- 🇺🇸 Hydro Research Peptides97
via Disclosed Labs · 10h ago
$9.80/mg +27.6% vs avg$490
50mg
- 🇺🇸 Profound Aminos95
via Disclosed Labs · 10h ago
$6.50/mg -15.4% vs avg$130
20mg
- 🇺🇸 Prime Peptides95
via Disclosed Labs · 10h ago
$8.67/mg +12.8% vs avg$130
15mg
- Nova Peptides94
via Disclosed Labs · 10h ago
$8.00/mg +4.1% vs avg$79.99
10mg
no purity - 🇺🇸 Polaris Peptides90
via Disclosed Labs · 10h ago
$8.25/mg +7.4% vs avg$165
20mg
- optimasupply.is86
via Disclosed Labs · 10h ago
$11.00/mg +43.2% vs avg$110
10mg
- 🇨🇳 Reta Peptide83
✓ verified at source · 9h ago
$6.50/mg -15.4% vs avg$65.00
10mg
- Modern Research Peptides82
via Disclosed Labs · 10h ago
$1.83/mg -76.1% vs avg$54.99
30mg
no purity - True Peptide82
via Disclosed Labs · 10h ago
$4.00/mg -47.9% vs avg$120
30mg
Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.
Watch Semaglutide
Get one email when the market actually moves — no newsletter, no noise.
About Semaglutide
CAS
910463-68-2
Molecular formula
C187H291N45O59
Typical dose range
0.25–2.4 mg (250–2400 mcg) subcutaneous once weekly; typically titrated from 0.25 mg/week, increasing every 4 weeks
Half-life
~7 days
COAs for Semaglutide
186 third-party tests across 28 vendors. Each card links to the full report.
For
Semaglutide
by Peptide Plugs· batch 189-02-DK
For
Semaglutide
by EZ Peptides· batch EZP-1P1007112026-04
For
Semaglutide
by Hydro Research Peptides· batch HR-2026-7341
For
Semaglutide
by Longeva· batch B-2026-SEMA-5-001
For
Semaglutide
by Peptide Partners· batch SPL-4149
For
Semaglutide
by Peptide Plugs· batch 125-01-SM
For
Semaglutide
by Soma Peptides· batch SEV052657
For
Semaglutide
by EZ Peptides· batch EZP-1P1005102026-03
For
Semaglutide
by EZ Peptides· batch EZP-1P1005102026-03
For
Semaglutide
by Blank Peptides· batch GS10-052026-4
For
Semaglutide
by Pepsgpt· batch P-2885342-P
For
Semaglutide
by Prime Peptides· batch 3022026SM
For
Semaglutide
by Prime Peptides· batch 3142026SM
For
Semaglutide
by Prime Peptides· batch 2242026SM
For
ION-1S
by Ion Peptide· batch ION1S20-04172026
For
Semaglutide
by Vertex Labs· batch SM0000038
For
Semaglutide
by OROS Research· batch OR-LPGLPS10-426-B3
For
Semaglutide
by Prime Peptides· batch 3272026SM
For
Semaglutide
by Prime Peptides· batch 3222026SX
For
Semaglutide
by Blank Peptides· batch 665394
For
Semaglutide
by Prime Peptides· batch 2182026SM
For
Semaglutide
by Prime Peptides· batch 2122026SM
For
Semaglutide
by Orbitrex Peptides· batch 1G200426
For
Semaglutide
by Qihang Peptide· batch 3
23 citations indexed for Semaglutide
meta-analysis · 2026
Burden and Risk of Depression in Patients Receiving Semaglutide: A Systematic Review and Meta-Analysis
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), including semaglutide, are widely used for Type 2 diabetes mellitus (T2DM), obesity and related metabolic conditions. Evidence on potential neuropsychiatric effects remains inconsistent.
meta-analysis · 2026
Comparative Efficacy of Tirzepatide Versus Semaglutide for Weight Loss in Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis of Head-to-Head Studies
This systematic review and meta-analysis aimed to compare the efficacy and safety of tirzepatide versus semaglutide for weight reduction in adults with overweight or obesity. We included randomised controlled trials and observational studies comparing tirzepatide and semaglutide with ≥ 24 weeks of follow-up.
animal · 2026
Females Are Completely Resistant to Semaglutide-Induced Muscle Loss in ob/ob Mice
Obesity is a major contributor to cardiometabolic disease, and pharmacological therapies, such as semaglutide, are increasingly used to induce weight loss.
animal · 2026
Electroacupuncture enables semaglutide dose sparing in type 2 diabetes by boosting drug concentration and suppressing β-cell apoptosis
Purpose Semaglutide is effective for type 2 diabetes mellitus (T2DM) but limited by dose-dependent gastrointestinal adverse effects.
Study · 2026
Association of Tirzepatide versus Semaglutide with Risk of Asthma Exacerbation in Patients with Asthma and Type 2 Diabetes: A US Multicenter Retrospective Cohort Study
Background While glucagon-like peptide-1 receptor agonists (GLP-1 RAs) show promise in improving respiratory outcomes, the comparative effectiveness of dual glucose-dependent insulinotropic polypeptide/GLP-1 RA versus GLP-1 RA alone remains unclear.
Study · 2026
IDE-mediated GLP-1 degradation as the basis for designing long-acting and CNS-stable GLP-1 receptor agonists
Glucagon-like peptide-1 (GLP-1) is a key incretin hormone rapidly degraded by circulating proteases such as DPP-4. The metabolism of GLP-1 by other proteases, particularly tissue-resident proteases, remains largely unexplored.